Eli Lilly Is Offering a Cheaper Form of Zepbound. What It Means for Hims & Hers Stock.
The new option is priced at a 50% or more discount compared to other weight-loss drugs.
What Is Going On With Hims & Hers Stock?
After a strong start to the year, the stock is down 30% since June.
Hims & Hers Health: Healthy Gift
Hims & Hers Health, Inc. reported booming sales in Q2, but the stock fell due to possible confusion on compounded GLP-1 drug sales. The online health and wellness platform dramatically hiked Q3 sales targets to over $375 million. The stock would trade at $41 based on trading at just 5x EV/S targets.
Hims & Hers: Great Value Amid Unwarranted Concerns (Rating Upgrade)
Hims & Hers stock has dropped ~30% from recent peaks despite raising its outlook for FY24. Investors are concerned over projections for the company's weight loss compound drugs, especially if the FDA-approved Wegovy and Ozempic see better supply. Still, the company's weight loss revenue is only contributing a small fraction of its outstanding growth rates today, built across a wide range of specialties.
Hims & Hers: Digesting Q2 2024 Earnings, Shares Still Undervalued, Rating Downgrade
Subscriber growth reaccelerated, focus on personalized products, over 40% subscribers use personalized solutions. Stock-based compensation concern, $100M buyback program, increased marketing spend, positive outlook for Hims' future. GLP-1 offering still in a gray area, path forward looks difficult but possible.
Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is Hims & Hers Health the Best Growth Stock for You?
Hims & Hers stock is trading based on speculation about its success with weight loss drugs. But that's a very small part of its business.
Prediction: Up 74% So Far This Year, This Weight Loss Stock Is About to Crater
Novo Nordisk and Eli Lilly are currently the major players in the weight loss market. Hims & Hers Health is looking to disrupt the space by offering a lower-cost alternative.
Hims & Hers Health Boosts Outlook. Is This a Golden Opportunity to Buy the Stock?
Hims & Hers' revenue and profit metrics soared in the second quarter. Growth is expected to accelerate in the second half following the launch of the company's GLP-1 offering.
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Hims & Hers Stock Crashed but This Is a Growth Machine
Don't overlook the 52% growth in the second quarter.
Hims & Hers Health, Inc. (HIMS) Q2 2024 Earnings Call Transcript
Hims & Hers Health, Inc. (NYSE:HIMS ) Q2 2024 Earnings Conference Call August 5, 2024 5:00 PM ET Company Participants Bill Newby - Head, IR Andrew Dudum - Co-Founder & CEO Yemi Okupe - CFO Conference Call Participants Maria Ripps - Canaccord Allen Lutz - Bank of America Jack Wallace - Guggenheim Securities Daniel Grosslight - Citi Jonna Kim - TD Cowen Aaron Kessler - Seaport Global Michael Cherny - Leerink Partners Jailendra Singh - Truist Securities Glen Santangelo - Jefferies George Hill - Deutsche Bank Korinne Wolfmeyer - Piper Sandler Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the Hims & Hers Second Quarter 2024 Earnings Conference Call.
